The purpose of this retrospective study was to identify the impact of oral anticoagulants on epistaxis with the focus on new oral anticoagulants.
The study was conducted at the Department for Ear- Nose- and Throat (ENT), Head and Neck Surgery, Technical University Munich, Germany. All patients presenting in 2014 with the diagnosis of epistaxis to a specialized ENT accident and emergency department were identified and analyzed in clinical data and medication.
600 adult cases, with a median age of 66.6 years were identified with active bleeding. 66.8% of all cases were anticoagulated. Classic oral anticoagulants (COAC) were three times more common in patients than new-generation oral anticoagulants (NOAC). Recurrent bleeding was significantly associated with oral anticoagulants (OAC) (p = 0.014) and bleeding location was most often anterior (p = 0.006). In contrast, severe cases, which required surgery or embolization were significantly more likely in non-anticoagulated middle-aged patients with posterior bleedings (p < 0.05). In our epistaxis cohort, OAC were highly overrepresented (40%) when compared to the general German population (1%) but COAC as well as NOAC played only a minor role in severe courses of epistaxis.
Oral anticoagulation, especially with new-generation drugs, is not associated with more complicated and severe courses of epistaxis, but rather with recurrent bleeding. One should keep this information in mind when triaging the patient in the emergency room and when planning further procedures.
Glaeske G, Schicktanz C (2015) Barmer GEK Krankenkasse—pharmacy report 2015. Siegburg Asgard- Verl.- Serv (ISBN: 978-3-943744-97-2)
Melia L, McGarry G (2008) Epistaxis in adults: a clinical review. Br J Hosp Med (Lond) 69(7):404–407 CrossRef
Cullen MM, Tami TA (1998) Comparison of internal maxillary artery ligation versus embolization for refractory posterior epistaxis. Otolaryngol Head Neck Surg 118(5):636–642 PubMed
Soyka MB, Nikolaou G, Rufibach K, Holzmann D (2011) On the effectiveness of treatment options in epistaxis: an analysis of 678 interventions. Rhinology 49(4):474–478 PubMed
Schwabe U, Paffrath D (2012) Pharmaceutical prescription 2012. Springer, Berlin
Bermüller C, Bender M, Brögger C, Petereit F, Schulz M (2014) Epistaxis and anticoagulation—a medical and economic challenge?. Laryngorhinootologie 93(4):249–255 PubMed
Soyka MB, Rufibach K, Huber A, Holzmann D (2010) Is severe epistaxis associated with acetylsalicylic acid intake? Laryngoscope 120(1):200–207 PubMed
Mancia G, Fagard R, Narkiewicz K et al. (2013) ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 31(10):1925–1938 CrossRef
Barnes ML, Spielmann PM, White PS (2012) Epistaxis: a contemporary evidence based approach. Otolaryngol Clin N Am 45(5):1005–1017 CrossRef
- The role of oral anticoagulants in epistaxis
A. M. S. Buchberger
- Springer Berlin Heidelberg
Neu im Fachgebiet HNO
e.Med Kampagnen-Visual, Mail Icon II